A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HER2 Positive Breast Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Masking Description: Investigators will determine HER2 expression by ABY-PET without knowledge of the results from the biopsies (in Phase III part).Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03655353
- Collaborators
- Roche Pharma AG
- Swedish Cancer Society
- Affibody
- Swedish Breast Cancer Group
- Investigators
- Principal Investigator: Henrik Lindman Uppsala University Hospital
Get Well Soon